<DOC>
	<DOCNO>NCT02645786</DOCNO>
	<brief_summary>The investigator evaluate cardiac effect Thyroid-stimulating hormone ( TSH ) over-suppression woman differentiate thyroid cancer ( DTC ) frequently encounter suppression therapy .</brief_summary>
	<brief_title>Thyrotropin Over-suppression Heart</brief_title>
	<detailed_description>The aim study evaluate cardiac effect TSH over-suppression woman DTC TSH suppressive therapy 5 9 year relative risk recurrence . Methods 1 . Patients From chart review , investigator select 96 female differentiate thyroid cancer patient receive total- near-total thyroidectomy , thereafter regularly visited endocrine out-patient department ( OPD ) Chuncheon Sacred Heart Hospital . Majority papillary thyroid cancer tend present 30 50 year old risk recurrence low intermediate . Menopause also might affect cardiovascular risk factor woman . According guideline , dose thyroxine would reduce 10 year thyroidectomy DTC patient . Therefore , additional enrollment criterion follow : 1 ) age le 45 year old receiving total near-total thyroidectomy , 2 ) serum level TSH &lt; 0.1 mU/L intermediate -risk TSH &lt; 0.3 mU/L low recurrence-risk group , 2 year study entry , 3 ) receive TSH suppressive therapy 5 9 year fix dose LT4 2 year study entry , 4 ) history structural heart disease , arrhythmia , cardiac symptom ( palpitation , exertional dyspnea chest discomfort ) therapy . Of 17 patient meet criterion , three patient consent study . Candidates satisfy enrollment criterion take electrocardiogram rule patient arrhythmia . Finally , 14 DTC patient enrol studied September 2009 March 2010 . As patient enrol , control subject select patient visit endocrinology department thyroid nodule work-up . The control group meet follow criterion : 1 ) subject match patient age ( ±2 year ) , sex , body mass index ( BMI ) ( ±2 kg/m2 ) , 2 ) within reference range serum TSH ( 0.3-4.6 mU/L ) , 3 ) history structural heart disease , arrhythmia , cardiac symptom , 4 ) history comorbid diseases affect thyroxine metabolism cardiac structure , include hepatic renal disease , anemia , hypertension . All subject meet enrollment criterion take electrocardiogram rule arrhythmias . Control subject recruit test January 2010 July 2011 . All participant provide write informed consent . 2 . Assays On examination day , participant prohibit smoke consume caffeine . After light breakfast medication , include levo-thyroxine ( LT4 ) cancer patient , participant visit hospital 9 AM . The investigator evaluate comorbid condition participant . Body weight height measure participant wear light clothing without shoe . The body mass index ( BMI ) calculate weight kilogram divide height meter square . Their blood pressure take 10 minute rest period . Subsequently , subject underwent 2-dimensional echocardiogram carry one examiner . After cardiac work-up , blood sample draw test thyroid function . Blood sample collect pre-chilled tube contain EDTA , immediately place ice , promptly centrifuge 4°C . After separation , plasma store -80°C N-terminal pro-brain natriuretic peptide ( NT-pro-BNP ) . Serum thyroid function test perform chemiluminescent immunoassay ( UNICELL DXI800 , Beckman Coulter , USA ) . Serum TSH ( reference value : 0.3-4.6 mU/L , detection limit : 0.0025 mU/L ) , free T4 ( reference value : 7.0-20.0 pmol/L ) , free T3 ( reference value : 4.0-5.9 pmol/L ) measure . Plasma NT-pro-BNP measurement do use chemiluminescent immunoassay method ( Roche E170 , Roche diagnostics , Germany ) 3 . Echocardiography Comprehensive transthoracic echocardiography perform use commercially available equipment ( IE33 , Philips Medical System , Andover , Massachusetts ) . Standard 2-dimensional measurement obtain recommended American Society Echocardiography ( ASE ) leave lateral position . Left atrial volume index measure biplane area-length method . Left ventricular ( LV ) mass calculate use follow equation : LV mass = 0.8 ( 1.04 { [ LVIDd + PWTd + IVSd ] 3 - [ LVIDd ] 3 } ) + 0.6 , LVID LV end-diastolic dimension , PWT posterior wall thickness , IVS interventricular septal wall thickness , diastole . Tissue Doppler-derived early diastolic mitral annular velocity ( e ' ) late diastolic mitral annular velocity ( ' ) measure septal corner mitral annulus apical 4-chamber view . To evaluate global longitudinal strain ( GLS ) leave ventricle , echocardiographic image obtain apical 4-chambers view strain analyze base routine DICOM ( Digital Imaging Communications Medicine ) data set use software ( 2D Cardiac Performance Analysis , TomTec , Munich , Germany ) . A region interest manually place endocardial epicardial border . The echocardiographic data gather analyzed 2 experienced echocardiographers unaware correspond clinical data . Statistical analysis Data report mean standard deviation ( SD ) . For comparison mean group , use Mann-Whitney test sample size small ( n=14 group ) . All P value calculate two-tailed consider significant P &lt; 0.05 . All statistical analysis perform use SPSS 20.0 software ( SPSS Inc , Chicago , USA ) .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Thyrotoxicosis</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<criteria>thyroid cancer group 1. age less 45 year old receiving total neartotal thyroidectomy , 2. serum level TSH &lt; 0.1 mU/L intermediate risk TSH &lt; 0.3 mU/L low recurrencerisk group 2 year study entry , 3. receive TSH suppressive therapy 5 9 year fix dose LT4 2 year study entry , 4. history structural heart disease , arrhythmia , cardiac symptom ( palpitation , exertional dyspnea chest discomfort ) therapy . control group 1. subject match patient age ( ±2 year ) , sex , body mass index ( BMI ) ( ±2 kg/m2 ) , 2. within reference range serum TSH ( 0.34.6 mU/L ) , 3. history structural heart disease , arrhythmia , cardiac symptom , 4. history comorbid diseases affect thyroxine metabolism cardiac structure , include hepatic renal disease , anemia , hypertension . arrhythmia electrography history cardiac disease</criteria>
	<gender>Female</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>thyroid neoplasm</keyword>
	<keyword>heart</keyword>
	<keyword>thyroxine</keyword>
	<keyword>thyrotoxicosis</keyword>
</DOC>